On July 16, Centene rose 5.15% in pre-market trading, trading at $69.52/share, with turnover of $1.1675 million. The stock rebounded sharply following a sector-wide recovery in managed health care names after the prior session's collective selloff.

The managed health care sector staged a broad-based rebound, with peers UnitedHealth up 6.17%, Humana up 6.45%, Molina Healthcare up 3.7%, and Elevance Health up 1.79%. The prior trading day saw systemic selling pressure driven by concerns over Elevance Health's Medicaid business, which dragged Centene down more than 7% in a single session. Elevance Health had reported rising costs across autism treatment, emergency room usage, outpatient surgery, and specialty pharmaceuticals, triggering sector-wide risk-off sentiment.

Centene's fundamentals remain intact. The company reported Q1 adjusted EPS of $3.37, significantly beating the consensus estimate of $2.13, and raised full-year guidance to above $3.40 versus the prior Street estimate of $3.02. Multiple investment banks have recently raised price targets to the $60-$80 range, with Truist setting a $78 target and Deutsche Bank at $80. Additionally, the company's Meridian unit secured a four-year Illinois Medicaid managed care contract running through 2030.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)